Bone Scan Index: a prognostic imaging biomarker for high-risk prostate cancer patients receiving primary hormonal therapy by unknown
Kaboteh et al. EJNMMI Research 2013, 3:9
http://www.ejnmmires.com/content/3/1/9ORIGINAL RESEARCH Open AccessBone Scan Index: a prognostic imaging biomarker
for high-risk prostate cancer patients receiving
primary hormonal therapy
Reza Kaboteh1*, Jan-Erik Damber2, Peter Gjertsson1, Peter Höglund3, Milan Lomsky1, Mattias Ohlsson4
and Lars Edenbrandt1,5Abstract
Background: The objective of this study was to explore the prognostic value of the Bone Scan Index (BSI) obtained
at the time of diagnosis in a group of high-risk prostate cancer patients receiving primary hormonal therapy.
Methods: This was a retrospective study based on 130 consecutive prostate cancer patients at high risk, based on
clinical stage (T2c/T3/T4), Gleason score (8 to 10) and prostate-specific antigen (PSA) (> 20 ng/mL), who had
undergone whole-body bone scans < 3 months after diagnosis and who received primary hormonal therapy. BSI
was calculated using an automated method. Cox proportional-hazards regression models were used to investigate
the association between clinical stage, Gleason score, PSA, BSI and survival. Discrimination between prognostic
models was assessed using the concordance index (C-index).
Results: In a multivariate analysis, Gleason score (p = 0.01) and BSI (p < 0.001) were associated with survival, but clinical
stage (p = 0.29) and PSA (p = 0.57) were not prognostic. The C-index increased from 0.66 to 0.71 when adding BSI to a
model including clinical stage, Gleason score and PSA. The 5-year probability of survival was 55% for patients without
metastases, 42% for patients with BSI < 1, 31% for patients with BSI = 1 to 5, and 0% for patients with BSI > 5.
Conclusions: BSI can be used as a complement to PSA to risk-stratify high-risk prostate cancer patients at the time of
diagnosis. This imaging biomarker, reflecting the extent of metastatic disease, can be of value both in clinical trials and
in patient management when deciding on treatment.
Keywords: Image analysis, Radionuclide imaging, Bone metastases, Prostate cancerBackground
Life expectancy is a major factor to be considered in the
management of prostate cancer patients. Risk stratifica-
tion schemes based on clinical T stage, Gleason score
and prostate-specific antigen (PSA) are widely used to
estimate risk in individual patients. The extent of bone
metastases is also associated with survival [1,2], but
there has not been any clinically useful technique of
quantifying the skeletal tumour burden and including this
information in the risk assessment. Bone scintigraphy,
however, is commonly used to assess skeletal tumour* Correspondence: kaboteh@gmail.com
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in any medium, provided the original work is pburden in prostate cancer patients, both in clinical routine
and in nearly every clinical trial. In order to extract as
much clinical information as possible from the bone
scans, the Bone Scan Index (BSI) was developed as a
quantitative tool to improve the interpretability and clin-
ical relevance of the bone scan [3]. BSI is a method of
expressing the tumour burden in the bone as a percentage
of the total skeletal mass.
BSI has recently been presented as a response indica-
tor in patients with castration-resistant metastatic pros-
tate cancer who have received chemotherapy [4]. The
patients had bone scans at baseline and at 3-month and
6-month follow-up, and BSI changes post-treatment were
a significant prognostic factor for survival. A doubling of
BSI post-treatment resulted in a 1.9-fold increase in the
risk of death. These results showed the feasibility ofan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 1 Patient characteristics (n = 130)
Patient characteristic Value
Age (years), median (IQR) 76.0 (69 to 84)
BSI
BSI = 0 (M0), no. (%) 72 (55)
BSI > 0 (M1), no. (%) 58 (45)
BSI > 0 (M1), median (IQR) 1.7 (0.7 to 7.4)
PSA (ng/mL), median (IQR) 59 (23 to 232)
Clinical T stage (n = 129)
T1, no. (%) 19 (15)
T2, no. (%) 29 (22)
T3, no. (%) 54 (42)
T4, no. (%) 27 (21)
Gleason score (n = 127)
6, no. (%) 6 (5)
7, no. (%) 47 (37)
8, no. (%) 30 (24)
9, no. (%) 35 (28)
10, no. (%) 9 (7)
BSI, Bone Scan Index; IQR, interquartile range; PSA, prostate-specific antigen;
M, M category in staging system for prostate cancer spreading to distant parts
of the body.
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measure and thereby allowing bone scans to be explored
as imaging biomarkers. Furthermore, changes in BSI post-
treatment were significantly associated with survival, but
post-treatment changes in PSA were not, while adjusting
for changes in BSI.
In order to improve the usefulness of BSI, we recently
presented a fully automated method of quantifying BSI
[5]. The automated method was evaluated in a group of
newly diagnosed prostate cancer patients, and BSI
increased the predictive accuracy for death as a result of
prostate cancer when added to a model containing pre-
treatment clinical stage, Gleason score and PSA. The 5-
year probability of dying as a result of prostate cancer
was under 6% for patients with BSI < 0.1 and over 78%
for patients with BSI > 1.0 at the time of diagnosis. Ini-
tial treatment may influence outcomes, and that was not
adjusted for in our previous study. Furthermore, low-
and intermediate-risk patients (median PSA = 16.8 ng/
mL) were included, and many of these patients probably
had a specific indication for receiving a bone scan, for
example, bone pain. This may have resulted in a selec-
tion bias. High-risk patients at the time of diagnosis have
been referred for bone scans before treatment decisions
as part of the clinical routine. The purpose of this study
was to explore the prognostic value of BSI obtained at
the time of diagnosis in a group of high-risk prostate
cancer patients receiving primary hormonal therapy.
Methods
Patients
All patients with the diagnosis of prostate cancer who,
during the period 2002 to 2008, had undergone a whole-
body bone scan < 3 months from the time of diagnosis
at the Sahlgrenska University Hospital, Gothenburg,
Sweden, were retrospectively considered for inclusion in
the study. Only patients at high risk who received pri-
mary hormonal therapy were included (chemical or sur-
gical castration (n = 97), anti-androgen deprivation as
monotherapy (n = 13), total androgen blockade (n = 11),
neoadjuvant treatment before curative treatment (n = 6),
a combination of external irradiation with anti-androgen
deprivation (n = 2), radical prostatectomy (n = 1)). None
of the patients had received any type of PCa treatment
prior to the bone scan. We defined patients as high-risk
if at least one of the following criteria was met [6]:
 T2c/T3/T4
 Gleason score 8 to 10
 PSA level > 20 ng/mL
In total, 130 patients were included in our analysis. Pa-
tient characteristics are presented in Table 1. During the
study period, patients at high risk at the time ofdiagnosis were referred for bone scan examination be-
fore treatment decisions as part of the clinical routine.
The study was approved by the Research Ethics Com-
mittee at Gothenburg University.
Data collection
Overall survival was defined as the time from bone scan
examination to death from any cause. Survival data and
PSA values collected from the computerised medical
records were updated until 24 September 2010. A total
of 76 were dead at follow-up with a median survival
time of 2.7 years (IQR 1.6 to 4.2) and 54 were alive with
a median follow-up time of 5.1 years (IQR 3.9 to 8.5).
Data on clinical T stage and Gleason score at the time of
diagnosis were collected from the Swedish National
Cancer Registry [7].
The percentage of the skeleton affected by tumour
mass in a bone scan was measured by calculating the
BSI. We have recently presented an automated method
[5] based on the clinically validated methodology for
manually computing BSI as presented by a group at the
Memorial Sloan-Kettering Cancer Center in New York
[3,8,9]. The automated method is trained to mimic an
expert reader in distinguishing hotspots due to metasta-
ses from those caused by factors such as degenerative
disease or fractures. Manual correction was required in
less than 5% of the patients to exclude hotspots clearly
misclassified and representing features such as a very
large urinary bladder, a urinary catheter attached to a
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intervention was applied. The method is implemented in
the commercially available software package EXINI
bone™ (EXINI Diagnostics AB, Lund, Sweden).Statistical methods
Cox proportional-hazards regression models were used
to investigate the association between clinical stage,
Gleason score, PSA, BSI and survival, both in univariate
and multivariable modelling. Hazard ratios were esti-
mated from the Cox models together with 95% confi-
dence intervals. The concordance index (C-index) was
used to discriminate between the different survival mod-
els [10]. The significance of a difference in C-index be-
tween different models was calculated using the method
described by Haibe-Kains et al. [11].
Kaplan-Meier estimates of the survival function were
used together with the log-rank test to indicate a signifi-
cant difference between four groups of patients: without
metastases (M0), with BSI < 1, BSI = 1 to 5 and BSI > 5.
The BSI levels 1 and 5 were used to categorize the
patients since that resulted in approximately the same
number of patients in each of the metastatic groups.
The survival rate expected in a group of men in the
general population with the same age as the M0 group
was calculated. This control survival curve of the general
Swedish population was generated using the Hakulinen
method [12], using data collected from the administra-
tive agency Statistics Sweden. This group is similar to
the M0 group with respect to other possible factorsFigure 1 Three patients, one each from the groups BSI < 1, BSI = 1 to
8.1, respectively.affecting survival, except for the patients of the M0
group having prostate cancer.
In the survival analysis, data were censored at a
follow-up time of 5 years. All analyses were carried out
using the R statistical computing environment.Results
The 5-year probability of survival was 41% in the total
group of high-risk patients. Metastatic disease was
present in 58/130 (45%) of the patients. The 5-year sur-
vival probabilities were 24% and 55% in patients with
(M1) and without (M0) metastases, respectively. Consid-
ering the tumour burden, measured using the continu-
ous variable BSI, and not only the presence of
metastases (M0 or M1), it was possible to divide the
metastatic group. We divided this group into three sub-
groups in order to have approximately 20 patients in
each subgroup: BSI < 1 (n = 22), BSI = 1 to 5 (n = 16)
and BSI > 5 (n = 20). Figure 1 shows one patient from each
of these subgroups illustrating the extent of disease. The
Kaplan-Meier curves for patients M0, BSI < 1, BSI = 1 to
5 and BSI > 5 were significantly different (p < 0.001), and
the 5-year survival probabilities were 55%, 42%, 31% and
0%, respectively. The survival curve for the M0 patients is
above the corresponding survival curve for the general
male population of the same age for the first 4 years
(Figure 2). The corresponding value for an age-matched
control cohort was 65%.
In the univariate analysis clinical stage, Gleason score,
PSA and BSI were all associated with survival (Table 2).5 and BSI > 5. The actual BSI values were 0.7, 2.2 and
Figure 2 Kaplan-Meier curves showing patient-survival probability stratified by BSI categories. The difference between the four groups of
patients without metastases (M0) and with metastases BSI < 1, BSI = 1 to 5 and BSI > 5 was statistically significant (p < 0.001). The broken line
shows an age-matched control survival curve for the M0 group.
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BSI (p < 0.001) were associated with survival, but clinical
stage (p = 0.29) and PSA (p = 0.57) were not prognostic.
The C-index increased from 0.66 to 0.71 (p = 0.006)
when adding BSI to a model including clinical stage,
Gleason score and PSA.Table 2 Survival analysis demonstrating association




Hazard ratio P value
Univariate analysis
Clinical T stage 129 1.53 (1.17 to 1.99) 0.002
Gleason score 127 1.39 (1.10 to 1.76) 0.006
PSA 130 1.0003 (1.0001 to 1.0005) 0.001
BSI 130 1.21 (1.14 to 1.28) < 0.001
Multivariate analysis
Clinical T stage 126 1.34 (1.02 to 1.77) 0.04
Gleason score 126 1.36 (1.07 to 1.73) 0.01
PSA 126 1.0003 (1.0001 to 1.0005) 0.006
Multivariate analysis
Clinical T stage 126 1.17 (0.87 to 1.57) 0.29
Gleason score 126 1.37 (1.07 to 1.75) 0.01
PSA 126 1.0000 (0.9998 to 1.0003) 0.57
BSI 126 1.19 (1.12 to 1.28) < 0.001Discussion
BSI includes prognostic information in addition to that
obtained from clinical T stage, Gleason score and PSA.
Patients with metastatic disease and BSI < 1 showed a
5-year probability of survival of 42% compared to 31%
for those with BSI = 1 to 5 and 0% for those with BSI > 5.
These findings show that a quantitative measurement
of tumour burden in the skeleton can be used to
risk-stratify patients more efficiently than only using
M-staging based on evidence of the presence or absence
of metastatic spread.
The added value of BSI was shown as an increase in
C-index from 0.66 to 0.71 when adding BSI to a model
including clinical T stage, Gleason score and PSA. This
is in agreement with the results presented by Ulmert
et al. [5], where the corresponding increase when adding
BSI was of the same magnitude, but from a higher level
(0.77 to 0.82). The higher values in the Ulmert study are
likely to be due to the fact that death as a result of pros-
tate cancer was used in that study, while all-cause mor-
tality or overall survival was used in this one. The cause
of death for the patients was not available in this retro-
spective study. Furthermore, the common primary end
point in large clinical trials exploring the effects of drugs
for prostate cancer patients is ‘overall survival’. This
study showed the value of BSI in a homogenous group
of prostate cancer patients, with those at high risk re-
ceiving primary hormonal therapy. In the Ulmert study,
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was not adjusted for.
The sensitivity for metastatic disease of bone scans is
regarded to be high, that is, the number of false-negative
cases is low, but some of our M0 patients are probably
falsely classified as M0. These patients might at least
partly contribute to the higher mortality in the M0
population after 4 years in comparison with the age-
matched control group. A follow-up bone scan to valid-
ate the BSI from the time of diagnosis could therefore
be of value. Change in BSI over time can also contain
important information in the M1 group. Dennis et al. re-
cently showed that on-treatment change in BSI was
associated with overall survival for patients receiving
chemotherapy [4]. Their study also showed that changes
in PSA were not associated with survival while adjusting
for changes in BSI.
Recently, another study demonstrated the value of BSI
in patients with castration-resistant prostate cancer [13].
In a group of 42 patients who underwent taxane-based
chemotherapy, reduction of BSI after treatment was
associated with longer overall survival. The findings of
recent BSI studies show the value of this imaging bio-
marker in both at the time of diagnosis and at a later
stage of the disease.
Based on the results of the present study, BSI can be
considered as an informative predictor of patient sur-
vival in men with high-risk disease treated with hormo-
nal therapy. BSI can also be of value in clinical trials as
an inclusion criterion so that baseline prognosis in treat-
ment and placebo groups can be matched.
The purpose of this study was to generate evidence
regarding how BSI can be used to risk-stratify prostate
cancer patients by applying an automated software to
bone scans - the established method of evaluating skel-
etal metastases. Bone scans are widely used in both clin-
ical routine and clinical trials, but the methodology has
its shortcomings. The radiotracer locates not tumour
cells but regions of the skeleton that are actively under-
going tissue repair - a well-known sign of tumour in-
volvement. Future developments in diagnostic imaging
may provide improved and more specific methods of
analysing skeletal lesions, including three-dimensional
methods such as SPECT/CT and PET/CT. At present,
bone scan is the dominant clinical method for evaluation
of skeletal metastases. Furthermore, prognostic studies
based on large patient groups and long follow-up time
are not currently available for the new modalities. This
type of bone scan study, showing that imaging can be
used as a biomarker, will be important in terms of gain-
ing experience, which can also be of value when new im-
aging modalities become widely used.
This study was based on a fully automated software for
calculation of tumour burden in patients with metastaticdisease. With this technique, widespread use in clinical
routine and clinical trials is possible. Operator-dependent
subjectivity in interpretation of bone scans, which has
proved to be substantial [14], is eliminated, and a reprodu-
cible analysis can be obtained at different hospitals. The
software has proved to be capable of differentiating be-
tween malignant lesions and hotspots due to degenerative
disease, e.g. by considering whether uptake in the shoulder
regions is symmetrical. In this study, only obvious false
lesions were manually corrected, e.g. a very large urinary
bladder, a urinary catheter attached to a drainage bag or
urine contamination. The quality of the software was
assessed in a study by Sadik et al. [15]. This study showed
that 35 physicians improved their sensitivity to metastatic
disease from 78% to 88% using the software for automated
analysis of bone scans.Conclusions
In conclusion, this study showed that BSI is strongly
associated with overall survival in patients with high-risk
prostate cancer receiving primary hormonal therapy and
that BSI includes prognostic information in addition to
clinical T stage, Gleason score and PSA. This study
builds on previous studies and generates evidence that
contributes to qualification of BSI as an imaging bio-
marker in prostate cancer patients. This biomarker has re-
cently become automated and thus highly reproducible,
eliminating operator-dependent subjectivity and providing
prognostic information with a processing time < 10 s.
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